Bicara Therapeutics Inc. Share-based Payment Arrangement, Expense
Bicara Therapeutics Inc. (BCAX) reported Share-based Payment Arrangement, Expense of $8.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- Bicara Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $8.24M, a 135.91% increase year-over-year.
- Bicara Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $5.86M, a 69.75% increase year-over-year.
- Bicara Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $4.45M, a 39.86% increase year-over-year.
- Bicara Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $3.61M, a 77.94% increase year-over-year.
- Bicara Therapeutics Inc. share-based payment arrangement, expense for fiscal 2025 was $15.01M, a 102.87% increase from fiscal 2024.
- Bicara Therapeutics Inc. share-based payment arrangement, expense for fiscal 2024 was $7.40M, a 289.52% increase from fiscal 2023.
- Bicara Therapeutics Inc. share-based payment arrangement, expense for fiscal 2023 was $1.90M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.24M 10-Q · filed 2026-08-11 | $14.10M 10-Q · filed 2026-08-11 | $18.55M derived: sum of 3 quarters · filed 2026-08-11 | $22.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $5.86M 10-Q · filed 2026-05-11 | $10.31M derived: sum of 2 quarters · filed 2026-05-11 | $13.92M derived: sum of 3 quarters · filed 2026-05-11 | $17.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $8.06M derived: sum of 2 quarters · filed 2026-03-30 | $11.55M derived: sum of 3 quarters · filed 2026-08-11 | $15.01M 10-K · filed 2026-03-30 |
| 2025-09-30 | $3.61M 10-Q · filed 2025-11-10 | $7.11M derived: sum of 2 quarters · filed 2026-08-11 | $10.56M 10-Q · filed 2025-11-10 | $13.74M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $3.49M 10-Q · filed 2026-08-11 | $6.94M 10-Q · filed 2026-08-11 | $10.12M derived: sum of 3 quarters · filed 2026-08-11 | $12.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.45M 10-Q · filed 2026-05-11 | $6.63M derived: sum of 2 quarters · filed 2026-05-11 | $8.66M derived: sum of 3 quarters · filed 2026-05-11 | $9.70M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.21M derived: sum of 2 quarters · filed 2026-03-30 | $6.25M derived: sum of 3 quarters · filed 2026-03-30 | $7.40M 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.03M 10-Q · filed 2025-11-10 | $3.07M derived: sum of 2 quarters · filed 2025-11-10 | $4.22M 10-Q · filed 2025-11-10 | $4.98M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.04M 10-Q · filed 2025-08-12 | $2.19M 10-Q · filed 2025-08-12 | $2.95M derived: sum of 3 quarters · filed 2025-08-12 | $3.47M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.15M 10-Q · filed 2025-05-13 | $1.91M derived: sum of 2 quarters · filed 2025-05-13 | $2.43M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $765.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.28M derived: sum of 2 quarters · filed 2025-03-27 | $1.90M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $519.00K 10-Q · filed 2024-11-12 | $1.13M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |